International Society for Antiviral Research

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Tuesday, February 7, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Chronic obstructive pulmonary disease, ECCMID, Human, Viral load, Fiscal, ICAR, Half-life, SARS-CoV-2, Epidemiology, PK, International Society for Antiviral Research, Omicron, Upper respiratory tract infection, Data, Virus, Viral, Animal, Safety, RSV, Patient, Asthma, Housing, Ritonavir, HBV, Risk, Virology, European Congress of Mathematics, Congress, Ferret, HCV, Heart, Infection, Research, International Conference on Emerging Infectious Diseases, Antiviral Research, Conference, European, Pharmacokinetics, Medication, Pharmaceutical industry, Cryptocurrency, Video game, Vaccine, Perfume, SPRINT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.
  • For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET.
  • The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic.
  • Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021.

Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)

Retrieved on: 
Thursday, March 25, 2021
Health sciences, Health, Medical specialties, Clinical research, Drug discovery, Pharmaceutical industry, Lassa fever, International Society for Antiviral Research, Clinical trial

SEATTLE, March 25, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research (ICAR) Virtual Conference 2021.

Key Points: 
  • SEATTLE, March 25, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research (ICAR) Virtual Conference 2021.
  • Sean Amberg, PhD, Director of Biodefense Initiatives at Kineta, presented the clinical data establishing the safety, tolerability, and pharmacokinetic profile of LHF-535.
  • "We are encouraged by these positive clinical study results for LHF-535 as there are no therapeutic options for patients infected with Lassa fever.
  • Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs.